The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Clinical Study of Epoetin Beta to Chemotherapy-Induced Anemia (CIA) Patients
Official Title: A Phase Ⅲ Randomized Double-Blind Placebo-Controlled Study of Epoetin Beta for the Treatment of Chemotherapy-Induced Anemia (CIA) in Cancer Patients
Study ID: NCT00628043
Brief Summary: This is a study to investigate the clinical efficacy and safety of epoetin beta 36,000 IU compared with placebo when administrated subcutaneously (s.c.) once-weekly for 12 weeks to anemic patients with lung cancer or gynecologic cancer undergoing chemotherapy.
Detailed Description:
Minimum Age: 20 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Chubu Region, Chubu, , Japan
Chugoku/Shikoku Region, Chugoku/Shikoku, , Japan
Hokkaido/Tohoku Region, Hokkaido/Tohoku, , Japan
Kanto/Koshinetsu Region, Kanto/Koshinetsu, , Japan
Kinki/Hokuriku Region, Kinki/Hokuriku, , Japan
Kyushu Region, Kyushu, , Japan
Name: Yoshito Suzuki
Affiliation: Chugai Pharmaceutical
Role: STUDY_CHAIR